Immune checkpoint inhibitors (ICIs), such as those targeting PD-1/PD-L1 or CTLA-4 (3), represent a class of immunotherapy drugs that prevent tumour evasion of host tumour antigen-specific T cell immunity. Here, CTLA4 is linked to neoplasm.